Corriente Advisors, LLC
- SEC CIK
- 0001406718
- Latest filing
- Feb 14, 2024
The latest 13F from Corriente Advisors, LLC covers Q4 2023 (filed Feb 14, 2024) and reports no long positions. Livermore has 12 filings on Form 13F from this institution, going back to Q1 2021.
What changed in Q4 2023
Share counts compared with Q3 2023: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.
- New
- 0
- Added
- 0
- Reduced
- 0
- Sold out
- 2
- Est. −$3.45M
Top 5 holdings
Share of this quarter's portfolio value
This filing reports no long positions.
Biggest buys
New and added positions, by estimated amount bought
None this quarter.
Largest weight increases
New and added positions, by percentage points of the portfolio gained
None this quarter.
Biggest sells
Reduced and sold-out positions, by estimated amount sold
Metrics
13F metrics for Q4 2023, computed only from the numbers in the filings. Definitions below.
- Portfolio value
- $0
- −$3.45M (−100.0%) vs. prior quarter
- Positions
- 0
- −2 vs. prior quarter
- Top 10 concentration
- –
- Top 10 as share of value
- Turnover
- 0.0%
- Q4 2023, one quarter
- Average holding period
- –
- Weighted by value
How these are calculated
- Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
- Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
- Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
- Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q1 2021), so positions held before then are understated.
13F filings by quarter
12 quarters, going back to Q1 2021. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.
Peak $271.6M (Q1 2021)
| Quarter | Filed | Positions | Value | Top 3 holdings | Changes | Filing |
|---|---|---|---|---|---|---|
| Q4 2023 | Feb 14, 2024 | 0 | $0 | – | vs. Q3 2023 | SEC |
| Q3 2023 | Nov 14, 2023 | 2 | $3.45M | NXERGTIW | vs. Q2 2023 | SEC |
| Q2 2023 | Aug 9, 2023 | 2 | $10.9K | AURJOBY | vs. Q1 2023 | SEC |
| Q1 2023 | May 10, 2023 | 2 | $976.4K | AIBBAI | vs. Q4 2022 | SEC |
| Q4 2022 | Feb 15, 2023 | 0 | $0 | – | vs. Q3 2022 | SEC |
| Q3 2022 | Nov 15, 2022 | 0 | $0 | – | vs. Q2 2022 | SEC |
| Q2 2022 | Aug 16, 2022 | 0 | $0 | – | vs. Q1 2022 | SEC |
| Q1 2022 | May 16, 2022 | 1 | $1.62M | NBR | vs. Q4 2021 | SEC |
| Q4 2021 | Feb 15, 2022 | 2 | $8.33M | Crescent PT Energy CorpAPRN | vs. Q3 2021 | SEC |
| Q3 2021 | Nov 15, 2021 | 8 | $51.8M | CUESWNTFFP | vs. Q2 2021 | SEC |
| Q2 2021 | Aug 16, 2021 | 15 | $185.4M | MAXRCUEREPL | vs. Q1 2021 | SEC |
| Q1 2021 | May 18, 2021 | 10 | $271.6M | MAXRREPLCUE | – | SEC |
13D and 13G filings
Companies where Corriente Advisors, LLC reports owning 5% or more on Schedule 13D or 13G, and its latest filings.
Current stakes of 5% or more
Corriente Advisors, LLC does not currently report owning 5% or more of any company.
Latest filings
8 filings on file made by Corriente Advisors, LLC or listing it as a reporting person, newest first.
| Company | Filed (ET) | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| CUECue Biopharma, Inc. | Feb 14, 2022 | 13G/AOld format | – | – | – | SEC |
| TFFPTFF Pharmaceuticals, Inc. | Feb 14, 2022 | 13G/AOld format | – | – | – | SEC |
| CRDFCardiff Oncology, Inc. | Feb 14, 2022 | 13G/AOld format | – | – | – | SEC |
| TFFPTFF Pharmaceuticals, Inc. | Feb 16, 2021 | 13GOld format | – | New | – | SEC |
| CUECue Biopharma, Inc. | Feb 16, 2021 | 13GOld format | – | New | – | SEC |
| ATXSAstria Therapeutics, Inc. | Feb 16, 2021 | 13G/AOld format | – | – | – | SEC |
| BFXBowflex Inc. | Feb 16, 2021 | 13G/AOld format | – | – | – | SEC |
| CRDFCardiff Oncology, Inc. | Feb 16, 2021 | 13GOld format | – | New | – | SEC |